Clinical Trials Logo

Filter by:
NCT ID: NCT01639339 Completed - Lupus Nephritis Clinical Trials

Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis

BLISS-LN
Start date: July 12, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients with active lupus nephritis.

NCT ID: NCT01639001 Completed - Clinical trials for NSCLC (Non-small Cell Lung Cancer)

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Start date: September 29, 2012
Phase: Phase 3
Study type: Interventional

This is a Phase III, Randomized, Open-label, Efficacy and Safety Study of Crizotinib single agent versus Chemotherapy Regimens (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) in First-Line ALK (Anaplastic Lymphoma Kinase) Positive East Asian Non-Small Cell Lung Cancer Patients. The objective of the study is to demonstrate that Crizotinib is superior to first-line chemotherapy pemetrexed/cisplatin or pemetrexed/carboplatin in prolonging Progression Free Survival (PFS) in East Asian patients with advanced Non-Squamous NSCLC whose tumors harbor a translocation or inversion event involving the ALK (Anaplastic Lymphoma Kinase) gene locus.

NCT ID: NCT01638923 Completed - Metrorrhagia Clinical Trials

Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding

Start date: June 2012
Phase: Phase 3
Study type: Interventional

To evaluate efficacy and safety of a combined oral contraceptive of estradiol valerate and dienogest in the treatment of heavy menstrual bleeding

NCT ID: NCT01638910 Completed - Contraception Clinical Trials

Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects

Start date: June 2012
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of a combined oral contraceptive of estradiol valerate and dienogest in healthy female subjects.

NCT ID: NCT01637883 Recruiting - For Intervention Clinical Trials

Benzydamine HCl for Postoperative Sore Throat

POST
Start date: January 2011
Phase: Phase 3
Study type: Interventional

To evaluate the analgesic effect of benzydamine hydrochloride dripping on the endotracheal tube cuff for postoperative sore throat.

NCT ID: NCT01637688 Active, not recruiting - Cow Milk Allergy Clinical Trials

Growth and Plasma Amino Acids in Infants With CMPA and Treated With a Newly Innovated Amino Acid Formula

CMPA
Start date: April 1, 2013
Phase:
Study type: Observational

The purpose of this study is to determine growth and protein status of infants with cow's milk protein allergy and treated with a newly innovated amino acid formula compared to those with a commercial amino acid formula.

NCT ID: NCT01637324 Completed - HIV Testing Clinical Trials

Multidisciplinary Services to Enhance HIV Testing and Linkage to Care Among MSM

Start date: May 2011
Phase: N/A
Study type: Observational

Objectives 1. To determine the impact of MSM-targeted multidisciplinary services on uptake of HIV voluntary counseling and testing (VCT) 2. To determine the impact of MSM-targeted multidisciplinary services on the enrollment into care and retention of HIV-positive MSM Subject population: HIV-negative and HIV-positive MSM clients, age ≥18 years old, of the Thai Red Cross Anonymous Clinic (TRC-AC) in Bangkok Thailand, the Cipto Mangunkusumo Hospital in Jakarta, and the Sanglah Hospital in Bali, Indonesia Number of participants: 200 HIV-negative and 150 HIV-positive MSM participants

NCT ID: NCT01637259 Completed - HIV Clinical Trials

MARCH Renal Substudy

MARCHrenal
Start date: June 2012
Phase: Phase 4
Study type: Interventional

Chronic kidney disease (CKD) is an emerging problem in patients with treated HIV. Antiretroviral therapy associated renal dysfunction has been predominantly described in terms of reduced glomerular filtration (eGFR). Proteinuria is a key component of CKD and may occur in the absence of significant reductions in eGFR. This substudy is an exploration of changes in urinary protein excretion in a randomised, open-label study to evaluate the efficacy and safety of MVC as a switch for either nucleoside or nucleotide analogue reverse transcriptase inhibitors (N(t)RTI) or boosted protease inhibitors (PI/r) in HIV-1 infected individuals with stable, well-controlled plasma HIV-RNA while taking their first N(t)RTI + PI/r regimen of combination antiretroviral therapy (cART).

NCT ID: NCT01637233 Completed - HIV-1 Infection Clinical Trials

MARCH Central Nervous System Substudy

Start date: June 2012
Phase: N/A
Study type: Observational

This substudy is a prospective, observational, open-label, randomised study within the MARCH study. The purpose of this substudy is to investigate the changes in cerebral function parameters at 5 timepoints over 96 weeks of the three different treatment arms within the MARCH study. The investigators hypothesise that there will be improvements in cerebral function in those patients randomised, as part of the parent study, into the maraviroc arms. the assessments in this CNS substudy will include: 1. Neurocognitive function as assessed by a computerised testing battery called CogState; 2. changes in cerebral metabolites as measured via 1H Magnetic Resonance Spectroscopy (1H-MRS) In those randomised to the maraviroc arms (arms 2 and 3) there is an optional Lumbar puncture at week 48. The cerebrospinal fluid will be used to measure maraviroc levels and an ultrasensitive CSF HIV-1 viral load. These results will be matched with levels in the plasma.

NCT ID: NCT01636869 Completed - Clinical trials for Total Knee Arthroplasty

Plasma Concentrations of Bupivacaine After Peri-articular Injection in Total Knee Arthroplasty

Start date: July 2012
Phase: Phase 4
Study type: Interventional

Patients with knee arthroplasty usually performed under spinal anesthesia with a single-shot femoral nerve block and periarticular block, so we would like to know the plasma concentration of bupivacaine in these patients.